Exciting Results from Plus Therapeutics on REYOBIQ Trial
Key findings show REYOBIQ achieved a remarkable clinical benefit rate exceeding 75% across various important outcome measures.
Analysis indicates RNA sequencing and a reduction in circulating tumor cells align with observed tumor cell death.
Additionally, the treatment displayed a favorable safety profile, with no significant dose-limiting toxicities noted.
In a major update from an important clinical trial, Plus Therapeutics, Inc. has unveiled optimistic data concerning its innovative treatment, REYOBIQ, aimed at tackling leptomeningeal metastases (LM). This information was shared during a notable forum at a conference focusing on central nervous system interactions, revealing that this therapy could become a viable option for patients grappling with this challenging condition.
Plus Therapeutics, a clinical-stage biopharmaceutical company known for pioneering targeted radiotherapeutics, reported on the positive outcomes from the ReSPECT-LM Phase 1 single-dose escalation trial. This trial involved 29 subjects and exhibited the feasibility of using REYOBIQ to treat LM while demonstrating safety and encouraging efficacy signals.
Significant Clinical Findings from REYOBIQ Treatment
In the study titled, “Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (REYOBIQ) for the Treatment of Leptomeningeal Metastases: Results on Safety and Efficacy,” researchers documented crucial results gathered from patients receiving different doses of REYOBIQ, showcasing its potential.
Key Highlights from the Trial
Among the findings presented were impressive response rates; specifically, a radiographic response of 76% and an even higher clinical response rate of 87% up until day 112 of the trial. Additionally:
- CSF tumor cell enumeration assays showed a maximum 100% reduction in tumor cells at day 28 from baseline.
- Notably, five of the seven participants with a tumor cell enumeration response over 80% survived for at least one year.
- The median overall survival across several cohorts was noted as 9 months, which is a significant improvement compared to historical data reporting average survival times of around four months.
- Importantly, there were no serious dose-limiting toxicities in the initial cohorts, though one was observed at higher dose levels.
- The most common side effects identified throughout the trial were primarily grade 1 or 2 in severity.
Dr. Andrew Brenner, a key investigator in this research, emphasized the encouraging nature of these results, underscoring that initial cohorts showed exceptional tolerance at elevated doses. He expressed that these insights are crucial for progressing into further trials and potentially towards approval.
Understanding Leptomeningeal Metastases
Leptomeningeal metastases, although rare, are a grave concern for advanced cancer patients. They involve the spread of cancer to the central nervous system’s protective membranes. This condition afflicts about 5% of individuals with metastatic cancers, particularly stemming from breast, lung, and melanoma origins. Survivability rates often range from just two to six months, emphasizing the pressing requirement for new treatment alternatives.
What is REYOBIQ?
REYOBIQ, or rhenium Re186 obisbemeda, represents a cutting-edge injectable radiotherapy designed to deliver concentrated targeted radiation directly to CNS tumors with enhanced safety, projecting an optimistic outlook for patient recovery compared to existing therapies. Its design utilizes rhenium-186, chosen for its effective properties in targeting and destroying cancer cells while enabling real-time imaging capabilities.
This promising product is currently being explored for use in recurrent glioblastoma and pediatric brain cancers in addition to its application in LM, supported by various grants from esteemed institutions like the National Cancer Institute and the Cancer Prevention & Research Institute of Texas.
About CNSide Diagnostic, LLC
CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, plays a crucial role by developing advanced diagnostic tests to identify tumor cells metastasized to the central nervous system. Their innovative CNSide CSF assay allows for detailed analysis of tumor cells showcasing a commitment to improving the treatment landscape for patients dealing with leptomeningeal metastases.
About Plus Therapeutics
Based in Houston, Texas, Plus Therapeutics, Inc. focuses on developing targeted therapies aimed at serious CNS cancers, striving to boost clinical outcomes through novel approaches that integrate image-guided therapy with drug delivery systems. The company is dedicated to advancing its robust pipeline in the field, which includes tackling challenging conditions such as LM and recurrent glioblastoma.
By establishing strong partnerships, Plus Therapeutics ensures a reliable supply chain supporting the development and future commercialization of its promising products.
Frequently Asked Questions
What are the primary results from the REYOBIQ clinical trial?
The trial showed a clinical benefit rate of over 75%, with significant reduction in tumor cells and manageable safety profile.
How does REYOBIQ work?
REYOBIQ is a targeted radiotherapy that delivers high doses of radiation specifically to CNS tumors, minimizing off-target effects.
What is the significance of leptomeningeal metastases?
LM is a serious complication of advanced cancer, often leading to a very limited survival period due to few effective treatment options.
Who funded the ReSPECT-LM trial?
The trial is supported by a grant from the Cancer Prevention & Research Institute of Texas.
What is the future outlook for Plus Therapeutics?
The company is advancing into more trials aimed at further optimizing dosing and exploring approval for REYOBIQ.
